Monte Rosa Therapeutics (NASDAQ:GLUE) COO Jennifer Champoux Sells 2,175 Shares

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) COO Jennifer Champoux sold 2,175 shares of the business’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $20.00, for a total transaction of $43,500.00. Following the completion of the transaction, the chief operating officer owned 62,371 shares in the company, valued at approximately $1,247,420. This trade represents a 3.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Monte Rosa Therapeutics Stock Up 1.1%

NASDAQ:GLUE traded up $0.22 on Thursday, reaching $19.39. The stock had a trading volume of 1,184,250 shares, compared to its average volume of 696,389. The company has a market capitalization of $1.64 billion, a P/E ratio of -13.10 and a beta of 1.62. Monte Rosa Therapeutics, Inc. has a 1-year low of $3.90 and a 1-year high of $25.77. The stock has a fifty day moving average price of $18.12 and a 200-day moving average price of $18.16.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%.The company had revenue of $4.21 million for the quarter, compared to analyst estimates of $10.95 million. Sell-side analysts predict that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Several large investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD lifted its holdings in Monte Rosa Therapeutics by 10.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,118,904 shares of the company’s stock valued at $80,265,000 after buying an additional 481,844 shares during the period. Vanguard Group Inc. lifted its holdings in Monte Rosa Therapeutics by 8.6% in the fourth quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock valued at $50,905,000 after buying an additional 257,547 shares during the period. State Street Corp lifted its holdings in Monte Rosa Therapeutics by 148.9% in the fourth quarter. State Street Corp now owns 2,107,480 shares of the company’s stock valued at $33,045,000 after buying an additional 1,260,707 shares during the period. AQR Capital Management LLC lifted its holdings in Monte Rosa Therapeutics by 459.4% in the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock valued at $5,791,000 after buying an additional 1,054,406 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Monte Rosa Therapeutics by 4.6% in the fourth quarter. Geode Capital Management LLC now owns 1,204,844 shares of the company’s stock valued at $18,896,000 after buying an additional 53,278 shares during the period. 79.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on GLUE shares. Wells Fargo & Company reduced their target price on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. JPMorgan Chase & Co. upped their target price on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Wall Street Zen lowered shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Zacks Research lowered shares of Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 4th. Finally, Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $32.50.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.